Cargando…

Downregulation of miR-142a Contributes to the Enhanced Anti-Apoptotic Ability of Murine Chronic Myelogenous Leukemia Cells

BACKGROUND: Leukemic stem cell (LSC) is thought to be responsible for chronic myelogenous leukemia (CML) initiation and relapse. However, the inherent regulation of LSCs remains largely obscure. Herein, we integratedly analyzed miRNA and gene expression alterations in bone marrow (BM) Lin(-)Sca1(+)c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhiwei, Xie, Yinyin, Liu, Dan, Liu, Ping, Li, Fei, Zhang, Zhanglin, Zhang, Mengmeng, Wang, Xiaolin, Zhang, Yuanliang, Sun, Xiaojian, Huang, Qiuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354203/ https://www.ncbi.nlm.nih.gov/pubmed/34386429 http://dx.doi.org/10.3389/fonc.2021.718731

Ejemplares similares

Intra‐heterogeneity in transcription and chemoresistant property of leukemia‐initiating cells in murine Setd2(−/−) acute myeloid leukemia
por: Song, Jiachun, et al.
Publicado: (2021)

Upregulation of miR-142-3p Improves Drug Sensitivity of Acute Myelogenous Leukemia through Reducing P-Glycoprotein and Repressing Autophagy by Targeting HMGB1
por: Zhang, Yuan, et al.
Publicado: (2017)

Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells
por: Iskandarani, Ahmad, et al.
Publicado: (2016)

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019)

Integrative Analysis of Multi-Omics Identified the Prognostic Biomarkers in Acute Myelogenous Leukemia
por: Zheng, Jiafeng, et al.
Publicado: (2020)

Biomarkers for determining the prognosis in chronic myelogenous leukemia
por: Sweet, Kendra, et al.
Publicado: (2013)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells
por: Taverna, Simona, et al.
Publicado: (2014)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

Acute Myelogenous Leukemia and Febrile Neutropenia
por: Herbers, Alexandra, et al.
Publicado: (2009)

Neuroprotective effects of miR-142-5p downregulation against isoflurane-induced neurological impairment
por: Xie, Cuili, et al.
Publicado: (2020)

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
por: Long, Bing, et al.
Publicado: (2011)

Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells
por: Ji, Qing, et al.
Publicado: (2016)

Expression and Activity of Fyn Mediate Proliferation and Blastic Features of Chronic Myelogenous Leukemia
por: Singh, Melissa M., et al.
Publicado: (2012)

Applications of Microarray Technology to Acute Myelogenous Leukemia
por: Goswami, Rashmi S., et al.
Publicado: (2008)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
por: Janani, Gopalarethinam, et al.
Publicado: (2023)

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia
por: Liu, Yonglan, et al.
Publicado: (2022)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

miR-181a Post-Transcriptionally Downregulates Oncogenic RalA and Contributes to Growth Inhibition and Apoptosis in Chronic Myelogenous Leukemia (CML)
por: Fei, Jia, et al.
Publicado: (2012)

The microRNAs involved in human myeloid differentiation and myelogenous/myeloblastic leukemia
por: Wang, Xiao-Shuang, et al.
Publicado: (2008)

Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway
por: Li, Jie, et al.
Publicado: (2019)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation
por: Liesveld, Jane
Publicado: (2012)

Unusual T-Lymphoblastic Blast Phase of Chronic Myelogenous Leukemia
por: Xu, Jie, et al.
Publicado: (2014)

Acute Myelogenous Leukemia Mimicking Fulminant Periorbital Cellulitis
por: Bagheri, Abbas, et al.
Publicado: (2013)

The choice of first-line Chronic Myelogenous Leukemia treatment
por: Fava, Carmen, et al.
Publicado: (2015)

Primary hyperparathyroidism in a case of chronic myelogenous leukemia
por: Valizadeh, Nasim, et al.
Publicado: (2013)

Familial Adenomatous Polyposis Complicated by Acute Myelogenous Leukemia
por: Alkofahi, Ala A, et al.
Publicado: (2020)

Modulation of Akt and ERK1/2 Pathways by Resveratrol in Chronic Myelogenous Leukemia (CML) Cells Results in the Downregulation of Hsp70
por: Banerjee Mustafi, Soumyajit, et al.
Publicado: (2010)

Focal lymphoblastic transformation of chronic myelogenous leukemia develops into erythroid leukemia: A case report
por: Wang, Wei, et al.
Publicado: (2023)

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014)

LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia
por: Hu, Tingting, et al.
Publicado: (2022)

Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia
Publicado: (1978)

Cannot write session to /tmp/vufind_sessions/sess_snibsfa2cfuc2a52vp358dj5su